Autologous stem cell transplantation in elderly patients (&gt;=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry

Jantunen, Esa; Canals, Carme; Rambaldi, Alessandro; Ossenkoppele, Gert J.; Allione, Bernardino; Blaise, Didier; Conde, Eulogio; Tilly, Hervé; Cook, Guillermo; Clark, Fiona; Gallamini, Andrea; Haynes, AP; Mounier, Nicolas; Dreger, Peter; Pfreundschuh, M.; Sureda, Anna

doi:10.3324/haematol.13273

Cited by 94 publications

(63 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly to this data, there is increasing interest in performing ABSCT in older patients. In 2008, the EBMT Lymphoma Working Party showed that intensive chemotherapy followed by ABSCT is feasible in patients over 60 years and that age should not be considered as an exclusion factor [3]. This study confirmed previous data [12][13][14].…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

Peripheral blood stem cell collection in elderly patients

Tempescul

Ianotto²,

Hardy³

et al. 2009

Ann Hematol

View full text Add to dashboard Cite

Intensive treatments like autologous blood stem cell transplantations are standard consolidation treatments for lymphoma and myeloma in young people. The upper age limit for these procedures is constantly increasing. Instead of studying the impact of aging on harvesting peripheral blood stem cells (PBSC), we performed a retrospective study to explore the feasibility of collecting stem cells from patients older than 65 years and compared the efficacy to harvest in younger patients. During a period of 7 years, we identified 108 patients with myeloma or lymphoma who were older than 65 years who underwent PBSC collection. Only eight patients failed to produce a successful harvest. The majority of patients only needed one apheresis (71%). There was a median number of 5.3× 10 6 CD34+ cells/kg. Our study demonstrated that older patients can also undergo PBSC harvests similar to younger patients.

show abstract

Section: Discussionsupporting

confidence: 81%

“…The upper age limit for this procedure is constantly increasing [3]. ABSCT is the standard approach for several diseases including: non-Hodgkin's lymphoma, early relapsing follicular lymphoma, mantle cell lymphoma, and patients with aggressive B and T cell lymphomas expressing bad features at the time of diagnosis (high IPI).…”

Section: Discussionmentioning

confidence: 99%

Peripheral blood stem cell collection in elderly patients

Tempescul

Ianotto²,

Hardy³

et al. 2009

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…A recent study of 2,612 patients with DLBCL receiving ASCT included 463 patients more than 60 years of age, 23% of patients being in first CR and 71% in partial remission or second or higher CR (77). When compared with younger patients, nonrelapse mortality was higher in the elderly.…”

Section: Autologous Stem Cell Transplantationmentioning

confidence: 99%

Diffuse Large B-cell Lymphoma in the Elderly: A Review of Potential Difficulties

Sarkozy

2013

Clinical Cancer Research

View full text Add to dashboard Cite

Half of patients with diffuse large B-cell lymphoma (DLBCL) are more than 65 years old. These elderly patients frequently have other diseases, some of them severe, which may alter their ability to receive standard curative therapy. However, these associated diseases are heterogeneous and only a few contraindicate chemotherapy treatments. We reviewed all potential difficulties, such as the evaluation of comorbidities, the heterogeneous functional status of this population, and the consequences of the aging process that might be associated with treating these patients, and now propose solutions. As standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy may cure the majority of patients, it must always be the first proposed option. With this approach, elderly patients with DLBCL treated with a curative intent can reach a complete remission and have a similar outcome as younger patients. Reduced dose intensity must be applied for very elderly patients or those unfit for full-dose anthracycline. The critical question for a physician is why these patients cannot be treated with the standard regimen, namely R-CHOP.

show abstract

“…As such, these improvements have translated into a greater deployment of autologous HCT in patients above 60-65 years of age [8]. Contemporary registry data from the CIBMTR and the European Group for Blood and Marrow Transplantation seem to validate this practice, with seemingly no increased TRM or compromised survival outcomes in patients >65 years of age undergoing auto-HCT in patients with aggressive NHL [9], mantle cell lymphoma [10], indolent lymphomas [11] and Hodgkin lymphoma [8].…”

Section: Lymphomamentioning

confidence: 99%

Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age

Michaelis

Hamadani

Hari

2014

Expert Review of Hematology

View full text Add to dashboard Cite

Autologous stem cell transplantation in elderly patients (>=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry

Abstract: BackgroundThere is currently limited experience on the feasibility and efficacy of autologous stem cell transplantation in elderly patients with diffuse large B-cell lymphoma.

Cited by 94 publications

References 26 publications

Peripheral blood stem cell collection in elderly patients

Peripheral blood stem cell collection in elderly patients

Diffuse Large B-cell Lymphoma in the Elderly: A Review of Potential Difficulties

Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age

Contact Info

Product

Resources

About